Tekgöz, EmreÇolak, SedaYardımcı, Kübra G.Küçükşahin, OrhanÇınar, MuhammetYılmaz, SedatKalyoncu, UmutMercan, Rıdvan2022-05-112022-05-1120221536-7355https://doi.org/10.1097/RHU.0000000000001699https://hdl.handle.net/20.500.11776/4880OBJECTIVE: Because of concerns about malignancy risks, using biological disease-modifying antirheumatic drugs (bDMARDs) in patients with a history of malignancy remains a challenging issue in rheumatology practice. This study aimed to investigate bDMARD preferences of physicians when treating of rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients with a history of malignancy. METHODS: The data for this cross-sectional study were gathered from the TReasure database using a date range of December 2017 and January 2020. Biological disease-modifying antirheumatic drug preferences were analyzed for 40 RA patients and 25 SpA patients with a history of malignancy. RESULTS: The most frequently prescribed bDMARD was rituximab, which was given to 28 RA patients (70%). For 25 patients (62.5%), the time between the diagnosis of malignancy and starting on a bDMARD regimen was less than 60 months, with a median interval of 43.5 months. Among SpA patients, the preferred bDMARDs were secukinumab and etanercept, which were each administered to 7 patients (28%). For 13 SpA patients (52%), the time between the diagnosis of malignancy and starting on bDMARDs was less than 60 months, with a median interval of 97 months. CONCLUSIONS: The observed bDMARD preferences may be related to the therapeutic effects of rituximab on lymphoproliferative malignancies, the protective effects of secukinumab on tumor progression, and the short half-life of etanercept. Biological disease-modifying antirheumatic drugs should be used in RA and SpA patients with malignancy in case of high inflammatory activity. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.en10.1097/RHU.0000000000001699info:eu-repo/semantics/closedAccessantirheumatic agentbiological productcross-sectional studyhumanneoplasmphysicianrheumatoid arthritisspondylarthritisAntirheumatic AgentsArthritis, RheumatoidBiological ProductsCross-Sectional StudiesHumansNeoplasmsPhysiciansSpondylarthritisArticle282e318e323Q3WOS:0007590799000102-s2.0-8512501860234014053Q2